Live Terminal
Telegram

Glenmark launches generic Inlyta tablets for kidney cancer treatment in US

Share on WhatsApp Telegram
⚡ Instant Key Takeaways (TL;DR)
🎯
Core Development: Glenmark launches generic Inlyta tablets for kidney cancer treatment in US
📊
Market & Financial Impact: Glenmark Axitinib tablets (a generic equivalent to Pfizer's Inlyta) are used to treat advanced renal cell carcinoma (RCC), a type of kidney cancer
💡
Actionable Insight: 🟢 Bullish Trigger: Positive business expansion or earnings beat may attract institutional and retail buying.

According to IQVIA sales data for the 12-month period ended September 2026, annual sales of Inlyta tablets in the US were around $538.4 million

Glenmark Pharmaceuticals Inc, USA, on Monday announced the launch of Axitinib Tablets in 1 mg and 5 mg strengths, a generic version of Pfizer Inc's Inlyta tablets.

Glenmark Axitinib tablets (a generic equivalent to Pfizer's Inlyta) are used to treat advanced renal cell carcinoma (RCC), a type of kidney cancer.

"The launch of Axitinib tablets reinforces Glenmark's commitment to expanding access to quality, affordable medicines for patients in the United States," said Marc Kikuchi, President & Business Head, North America.

By adding this product to its portfolio, the company continues to strengthen focus on addressing the evolving needs of patients and healthcare providers, he said.

📰
Official Publisher Attribution: This report is aggregated from Business Standard. ZeroLive provides live aggregation, automated sentiment synthesis, and exchange disclosure monitoring for retail market participants.
Read Original Full Coverage on Business Standard ↗
⚡
Get Breaking Stock Alerts & Q-Results on Telegram
Real-time 1200x675 image cards and financial filings delivered instantly.
Join @Zerolive_news ↗
Link copied to clipboard! ✅